Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Income from Continuing Operations: 2010-2025

Historic Income from Continuing Operations for Catalyst Pharmaceuticals (CPRX) over the last 15 years, with Sep 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Income from Continuing Operations rose 20.28% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 65.79%. This contributed to the annual value of $163.4 million for FY2024, which is 174.43% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Income from Continuing Operations stood at $52.8 million for Q3 2025, which was up 1.30% from $52.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Income from Continuing Operations registered a high of $56.7 million during Q1 2025, and its lowest value of -$30.8 million during Q3 2023.
  • For the 3-year period, Catalyst Pharmaceuticals' Income from Continuing Operations averaged around $35.0 million, with its median value being $40.8 million (2024).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 235.24% in 2023, then spiked by 242.65% in 2024.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Income from Continuing Operations stood at $9.3 million in 2021, then spiked by 173.62% to $25.5 million in 2022, then fell by 9.82% to $23.0 million in 2023, then soared by 141.33% to $55.4 million in 2024, then grew by 20.28% to $52.8 million in 2025.
  • Its Income from Continuing Operations was $52.8 million in Q3 2025, compared to $52.1 million in Q2 2025 and $56.7 million in Q1 2025.